A nutritional composition and its use in improving brain, nerve and cognitive development

Through nutritional compositions of medium and long-chain fatty acid triglycerides and casein phosphopeptides, the discomfort and ketoacidosis caused by high MCT dose in the prior art were solved, and the effects of MLCT and casein phosphopeptides on brain development have not been discussed. The problem has achieved a significant improvement in brain, nerve and cognitive development and is suitable for food or drug preparations.

CN118556870BActive Publication Date: 2024-11-19INNER MONGOLIA MENGNIU DAIRY IND (GROUP) CO LTD
View PDF 0 Cites 5 Cited by

Patent Information

Application Number
CN202411061792.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-19
Estimated Expiration
2044-08-05

AI Technical Summary

Technical Problem

In the prior art, long-chain polyunsaturated fatty acid (LCPUFA) and medium-chain triglyceride (MCT) compositions may contribute to improving cognitive function, but high-dose MCT may cause gastrointestinal discomfort and risk of ketoacidosis. , The role of medium and long-chain fatty acid triglycerides (MLCT) on brain cognitive development has not been fully discussed, and the role of casein phosphopeptide on brain development has not been reported.

Method used

A nutritional composition is provided that comprises a mass ratio of medium-long chain fatty acid triglycerides and casein phosphopeptides (8-145): 1 by mixing them to enhance synergistic effects of brain, nerve and cognitive development. , used to improve learning, memory and nervous system functions.

Benefits of technology

It significantly improves the effect of brain, nerve and cognitive development, can prevent or improve brain development delay, nervous system development delay and cognitive development delay, enhance learning and memory functions, and is suitable for food or drug preparations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention relates to the field of food technology, and in particular to a nutritional composition and its application in improving brain, nerve and cognitive development. The nutritional composition provided by the present invention comprises medium-chain fatty acid triglycerides and casein phosphopeptides. In the composition, the medium-chain fatty acid triglycerides and casein phosphopeptides act synergistically, significantly improving the effect of the composition on improving brain, nerve and cognitive development. The composition can be used to prevent or improve brain retardation and nervous system and cognitive development retardation; at the same time, it can also be used to prevent or improve impaired learning ability, impaired mental behavior, impaired memory or reduced attention span, etc., and has good application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of food technology, in particular to a nutritional composition and application thereof in improving brain, nerve and cognitive development. Background Art

[0002] The human brain is an important part of supervising learning, memory and movement. Neurons are interconnected to form a huge neural network, which is the basis of the nervous system including learning and memory. During development, especially in the first few years of life, infants and young children show interesting neurodevelopmental patterns and high neuroplasticity.

[0003] Early studies have shown that combinations containing one or more long-chain polyunsaturated fatty acids (LCPUFA) and medium-chain triglycerides (MCTs) can enhance cognitive function, reduce or prevent declines in social interaction, reduce or prevent age-related behavioral changes, increase trainability, maintain optimal brain function, promote learning and memory, and reduce memory loss (BRPI0818301B1). However, high-dose MCT administration can cause gastrointestinal discomfort, and long-term use of MCTs carries the risk of ketoacidosis or ketonemia. Medium-chain triglycerides (MLCTs) have one or two medium-chain fatty acids attached to the glycerol backbone, while the rest are long-chain fatty acids, accounting for about 30% of total triglycerides in breast milk. Early studies have shown that the fatty acid composition of MLCT is closer to breast milk, which is beneficial to fat digestion and absorption, improves the absorption of lipid nutrients, inhibits the accumulation of body fat, and can quickly and stably provide energy (Cheng X, Jiang C, Jin J, Jin Q, Akoh CC, Wei W, Wang X. Medium-and Long-Chain Triacylglycerol: Preparation, Health Benefits, and Food Utilization. Annu Rev Food Sci Technol. 2024 Jan 18; Ting Lan, Wei Wei, Ye Xingwang, Liu Zhengdong, Yan Zhiyuan, Jin Qingzhe, Wang Xingguo. Research Progress on Medium-and Long-Chain Triacylglycerols in Breast Milk [J]. Journal of Food and Biotechnology, 2022, 41(6): 41-50.). In addition, when the overall fatty acid composition of breast milk is the same, the structure of triglycerides is different, and their biological functions are also very different. For example, studies on mice have shown that compared with feeding a formula lipid feed containing LCT / MCT physical mixed vegetable oil with the same fatty acid composition, feeding a formula lipid feed containing human milk structured ester MLCT has the function of regulating mouse thermogenesis, inhibiting visceral fat accumulation, changing intestinal flora, and regulating lipid metabolism (Yuan T, Cheng X, Shen L, Liu Z, Ye X, Yan Z, Wei W, Wang X. Novel Human Milk Fat Substitutes Based on Medium- and Long-Chain Triacylglycerol Regulate Thermogenesis, LipidMetabolism, and Gut Microbiota Diversity in C57BL / 6J Mice. J Agric Food Chem. 2024 Mar 27; 72(12): 6213-622.), however, there are few reports on the effects of MLCT on brain cognitive development.

[0004] Casein phosphopeptide (CPP) is a biologically active peptide obtained from bovine casein through biotechnology. The CPP molecule is composed of twenty to thirty amino acid residues, including 4 to 7 clustered phosphopeptides. CPP has physiological functions such as promoting the absorption and utilization of minerals such as calcium, iron, magnesium, zinc, and selenium, preventing dental caries, and promoting in vitro fertilization of animals (Tang Yajie, Wu Sifang. Research Progress of Casein Phosphopeptide [J]. Food Science, 1998, 19(5):4.). However, no research has yet reported the effects of casein phosphopeptide on brain development, cognition, and neural development. Summary of the invention

[0005] The present invention provides a nutritional composition and its use in improving brain, nerve and cognitive development.

[0006] Specifically, the present invention provides the following technical solutions.

[0007] The present invention provides a nutritional composition, which comprises medium-chain fatty acid triglycerides and casein phosphopeptide in a mass ratio of (8-145):1.

[0008] The present invention finds that the nutritional composition comprising medium-chain fatty acid triglycerides and casein phosphopeptide has the function of significantly improving brain, nerve and cognitive development.

[0009] Preferably, in the nutritional composition, the mass ratio of medium-chain fatty acid triglycerides and casein phosphopeptide is (8-12): 1. The combination of medium-chain fatty acid triglycerides and casein phosphopeptide within this ratio range can produce a synergistic effect in improving brain, nerve and cognitive development. Compared with the effects of medium-chain fatty acid triglycerides and casein phosphopeptide alone, the effect of the combination of the two components on improving brain, nerve and cognitive development and enhancing learning and memory functions is significantly improved.

[0010] When the above-mentioned nutritional composition is orally administered to a human body, the dosage of medium-chain fatty acid triglycerides is 0.31-16.48 g / d, and the dosage of casein phosphopeptide is converted in proportion.

[0011] The present invention also provides a method for preparing the nutritional composition, which comprises the step of mixing medium- and long-chain fatty acid triglycerides and casein phosphopeptide.

[0012] Based on the function of the nutritional composition, the present invention provides any of the following applications of the nutritional composition:

[0013] The present invention provides the use of the nutritional composition in preparing a product for improving brain, nerve and / or cognitive development.

[0014] Preferably, the improving brain, nerve and / or cognitive development comprises preventing or improving brain developmental delay, nervous system developmental delay and / or cognitive developmental delay.

[0015] The present invention provides application of the nutritional composition in preparing a product for enhancing learning and / or memory function.

[0016] Preferably, the enhancement of learning and / or memory function is the prevention or improvement of impaired learning ability, impaired mental behavior, impaired memory and / or reduced attention span.

[0017] In the above application, the product is preferably food or medicine.

[0018] The food is a common food or a special food. The food includes but is not limited to dairy products, candies, beverages, fermented foods, bread, biscuits and other pasta products, etc.; preferably dairy products, such as milk powder, modified milk powder, formula powder or solid beverage, etc. The food can be in the form of powder, tablet or liquid.

[0019] The drug may be in any dosage form such as a solid preparation or a liquid preparation. Depending on the dosage form, the drug may also contain excipients permitted in the pharmaceutical field.

[0020] The present invention provides the use of the nutritional composition in improving brain, nerve and / or cognitive development for non-disease treatment purposes.

[0021] The present invention provides the use of the nutritional composition in enhancing learning and / or memory function for non-disease treatment purposes.

[0022] The present invention provides a product, which comprises the nutritional composition described above.

[0023] Preferably, the product is a food or a medicine.

[0024] The food is a common food or a special food. The food includes but is not limited to dairy products, candies, beverages, fermented foods, bread, biscuits and other pasta products, etc.; preferably dairy products, such as milk powder, modified milk powder, formula powder or solid beverage, etc. The food can be in the form of powder, tablet or liquid.

[0025] The drug may be in any dosage form, such as a solid preparation (powder, tablet, etc.) or a liquid preparation. Depending on the dosage form, the drug may also contain excipients permitted in the pharmaceutical field.

[0026] The beneficial effects of the present invention include at least: the present invention provides a nutritional composition that can improve brain nerve and cognitive development, the composition comprises medium-chain fatty acid triglycerides and casein phosphopeptides, in which the medium-chain fatty acid triglycerides and casein phosphopeptides act synergistically, significantly improving the effect of the composition on improving brain, nerve and cognitive development. The composition can be used to prevent or improve brain retardation and nervous system and cognitive retardation; at the same time, it can also be used to prevent and improve impaired learning ability, impaired mental behavior, impaired memory or reduced attention span, etc., and has good application prospects. DETAILED DESCRIPTION

[0027] In a specific embodiment of the present invention, a nutritional composition is provided, which comprises medium-chain fatty acid triglycerides and casein phosphopeptide in a mass ratio of (8-145):1.

[0028] Preferably, in the nutritional composition, the mass ratio of medium-chain fatty acid triglycerides and casein phosphopeptides is (8-12):1. In the nutritional composition, the ratio of medium-chain fatty acid triglycerides and casein phosphopeptides can be any specific value within the above range. Within the ratio range of (8-145):1, the nutritional composition containing medium-chain fatty acid triglycerides and casein phosphopeptides can play a significant role in improving the brain, nerves, and cognitive development; within the ratio range of (8-12):1, medium-chain fatty acid triglycerides and casein phosphopeptides can produce a synergistic effect in improving the brain, nerves, cognitive development, and enhancing learning and memory functions, thereby enhancing the above-mentioned efficacy of the composition.

[0029] In a specific embodiment, the medium-chain fatty acid triglycerides are provided by medium-chain fatty acid edible oil, that is, the nutritional composition contains medium-chain fatty acid edible oil and casein phosphopeptide, wherein, based on the amount of medium-chain fatty acid triglycerides contained in the medium-chain fatty acid edible oil, the mass ratio of medium-chain fatty acid triglycerides to casein phosphopeptide is (8-145):1, preferably (8-12):1.

[0030] In a specific embodiment, the present invention also provides a food containing the above nutritional composition.

[0031] The food is preferably a dairy product, which is obtained by adding the composition as a beneficial ingredient to dairy products such as milk powder.

[0032] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0033] Unless otherwise specified, the raw materials used in the present invention can be purchased from commercial sources, and the methods used are conventional methods in the art. In all the following embodiments, medium-chain fatty acid triglycerides are derived from medium-chain fatty acid edible oils with a purity of 69%, produced by Qingdao Haizhiyuan Life Science Co., Ltd., and the production batch number is Y1505-22120101; casein phosphopeptide purity is more than 95%, purchased from Guangzhou Green Cui Biology, and the production batch number is 240511001.

[0034] Example 1

[0035] This embodiment provides a nutritional composition comprising medium-chain fatty acid triglycerides and casein phosphopeptide in a mass ratio of 6:1.

[0036] Example 2

[0037] This embodiment provides a nutritional composition comprising medium-chain fatty acid triglycerides and casein phosphopeptide in a mass ratio of 8:1.

[0038] Example 3

[0039] This embodiment provides a nutritional composition comprising medium-chain fatty acid triglycerides and casein phosphopeptide in a mass ratio of 10:1.

[0040] Example 4

[0041] This embodiment provides a nutritional composition comprising medium-chain fatty acid triglycerides and casein phosphopeptide in a mass ratio of 12:1.

[0042] Example 5

[0043] This embodiment provides a nutritional composition comprising medium-chain fatty acid triglycerides and casein phosphopeptide in a mass ratio of 18:1.

[0044] Example 6

[0045] This embodiment provides a nutritional composition comprising medium-chain fatty acid triglycerides and casein phosphopeptide in a mass ratio of 25:1.

[0046] Example 7

[0047] This embodiment provides a nutritional composition comprising medium-chain fatty acid triglycerides and casein phosphopeptide in a mass ratio of 50:1.

[0048] Example 8

[0049] This embodiment provides a nutritional composition comprising medium-chain fatty acid triglycerides and casein phosphopeptide in a mass ratio of 68:1.

[0050] Example 9

[0051] This embodiment provides a nutritional composition comprising medium-chain fatty acid triglycerides and casein phosphopeptide in a mass ratio of 104:1.

[0052] Example 10

[0053] This embodiment provides a nutritional composition comprising medium-chain fatty acid triglycerides and casein phosphopeptide in a mass ratio of 145:1.

[0054] Experimental example

[0055] The present invention uses zebrafish animal experiments to verify the efficacy of the nutritional compositions of the above embodiments in improving brain, nerve and cognitive development. The specific experimental methods and results are described as follows.

[0056] 1. Determine the maximum detectable concentration (MTC) of the sample

[0057] To determine the MTC of medium-chain fatty acid triglycerides and casein phosphopeptides, wild-type AB strain zebrafish at 5 days post fertilization (dpf) were randomly selected in 6-well plates, and zebrafish were fed with medium-chain fatty acid triglycerides and casein phosphopeptides according to the sample concentrations described in Table 1, 30 zebrafish were treated in each group. After treatment at 28°C for 1 day, the number of zebrafish deaths and toxicity were observed to determine the MTC of the samples. The more serious the condition than the normal control group, the slower the movement of the zebrafish.

[0058] Table 1 Experimental results of maximum detection concentration (n=30)

[0059]

[0060] From the results in Table 1, it can be seen that the MTC of medium-chain fatty acid triglycerides is 690 μg / mL; the MTC of casein phosphopeptide is 76 μg / mL. The subsequent dosing experiment design was carried out with reference to the above MTC.

[0061] 2. Evaluation of efficacy in improving brain development

[0062] The zebrafish animal experiment method is as follows: wild-type AB strain zebrafish 5 days after fertilization (5dpf) were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well (experimental group). They were given single-component medium- and long-chain fatty acid triglycerides, single-component casein phosphopeptides and aqueous solutions of the nutrient composition, respectively. The positive control group was given Ginkgo biloba and Cistanche tablets (concentration 125μg / mL), and a normal control group was set up at the same time. After treatment at 28℃ for 1 day, 5 zebrafish were randomly selected from each experimental group and transferred to a plus maze. The movement trajectory of the zebrafish in each area was recorded with a behavior analyzer, and the statistical difference in the proportion of movement in the blue area was used to judge the efficacy of promoting brain development.

[0063] The maze is one of the important equipment for evaluating different phenomena (such as learning and memory, anxiety, preference, etc.) in zebrafish neurological disease models. Various cognitive tasks usually apply color clues in the maze to study zebrafish learning and memory. Color preference tests are often used in the evaluation of cognitive impairment in zebrafish. Zebrafish prefer short-wavelength colors. Compared with other colors (such as red, yellow, and green), zebrafish have a strong preference for blue. For zebrafish with cognitive dysfunction, changes in hormones and neurotransmitters in their brains cause the zebrafish to lose their preference for blue. In the above experiments, the statistical processing results are expressed as mean±SE; SPSS 26.0 software was used for statistical analysis. p <0.05 indicated that the difference was statistically significant.

[0064] According to the above method, medium-chain fatty acid triglycerides and casein phosphopeptides were administered to zebrafish at different doses to evaluate the efficacy of the two single components in improving brain development. The dosages and results are shown in Tables 2 and 3.

[0065] Table 2 Experimental results on the efficacy of single-component medium-chain fatty acid triglycerides in improving brain development

[0066]

[0067] Note: P The values ​​are the results of significant difference analysis between the positive control group or medium- and long-chain fatty acid triglyceride (MLCT) group and the normal control group.

[0068] Table 3 Experimental results on the efficacy of single-component casein phosphopeptide in improving brain development

[0069]

[0070] Note: P The values ​​are the results of significant difference analysis between the positive control group or casein phosphopeptide (CPP) group and the normal control group.

[0071] From the results in Tables 2 and 3, it can be seen that both medium-chain fatty acid triglycerides and casein phosphopeptides have the effect of improving brain development, which is specifically manifested as an increase in the proportion of movement in the blue area of ​​zebrafish. The optimal concentrations of medium-chain fatty acid triglycerides and casein phosphopeptides for improving brain development are 690µg / mL for medium-chain fatty acid triglycerides and 76µg / mL for casein phosphopeptides.

[0072] According to the above method, the nutritional composition of each example was administered to zebrafish to evaluate the efficacy of the nutritional composition in improving brain development. The dosage and results are shown in Table 4.

[0073] Table 4 Experimental results of the efficacy of the compositions of various embodiments in improving brain development

[0074]

[0075] Note: P The values ​​are the results of significant difference analysis between each embodiment group and the normal control group.

[0076] The above results show that compared with the normal control group, the compositions of Examples 2 to 10 all have the effect of improving brain development, which is specifically manifested in that the proportion of movement in the blue area of ​​zebrafish is significantly increased ( P <0.05). Compared with the effects of MLCT alone (concentration 690µg / mL) and CPP alone (concentration 76µg / mL) at the optimal concentration, the movement percentage values ​​of the blue area of ​​zebrafish in the MLCT and CPP compositions in Examples 2 to 10 were all increased. In particular, after administration of the compositions of Examples 2-4, the movement percentage of the blue area of ​​zebrafish was significantly higher than the movement percentage of the blue area of ​​MLCT alone (concentration 690µg / mL) and CPP alone (concentration 76µg / mL) at the optimal concentration ( P <0.05), that is, MLCT and CPP have a significant synergistic effect at the ratios of Examples 2-4.

[0077] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A nutritional composition, characterized in that The nutritional composition comprises medium-chain fatty acid triglycerides and casein phosphopeptide in a mass ratio of (8-25):

1.

2. The nutritional composition according to claim 1, characterized in that In the nutritional composition, the mass ratio of medium-chain fatty acid triglycerides to casein phosphopeptide is (8-12):

1.

3. Use of the nutritional composition according to claim 1 or 2 in the preparation of a product for improving brain or cognitive development.

4. The use according to claim 3, characterized in that: The product is a food or a medicine.

5. Use of the nutritional composition according to claim 1 or 2 in the preparation of a product for enhancing learning and / or memory function.

6. The use according to claim 5, characterized in that: The product is a food or a medicine.

7. Use of the nutritional composition according to claim 1 or 2 for improving brain or cognitive development for non-disease treatment purposes.

8. Use of the nutritional composition according to claim 1 or 2 for enhancing learning and / or memory function for non-disease treatment purposes.

9. A product, characterized in that The product comprises the nutritional composition according to claim 1 or 2.

10. The product according to claim 9, characterized in that The product is a food or a medicine.

Citation Information

Cited By

  • Nutritional composition and application thereof

    CN119896330A

  • Nutritional composition and use of the nutritional composition

    CN119896330B

  • Use of nutritional compositions for non-therapeutic purposes to increase neurotrophic factor expression

    CN122250667A

  • Use of nutritional compositions for non-therapeutic purposes to increase neurotrophic factor expression

    CN122271535A

  • Application of nutritional composition

    CN122375752A